For a complete list of risk factors that could cause Cutera's actual results to differ materially from the forward-looking statements, please refer to the section entitled Risk Factors in the company's most recent 10-Q filed on November 7, 2011, with the Securities and Exchange Commission. With that, I'll turn the call over to the company's President and Chief Executive Officer, Mr. Kevin Connors. Go ahead, Kevin.
Kevin P. Connors
Thank you, John. Good afternoon, everyone, and thanks for joining us today to discuss Cutera's results for the fourth quarter ended December 31, 2011. On today's call, I'll provide an overview of our company performance, then Ron Santilli, our CFO, will provide an overview of the financial results. Finally, I will provide some closing comments and open the call to your questions.
We are pleased with our fourth quarter 2011 revenue growth of 22%. Our U.S. revenue increased by 27%, and our international revenue improved by 19% compared to the fourth quarter 2010. This revenue improvement was a direct result of the following key initiatives. The first key contributor to our revenue growth last quarter was the sales management changes that we implemented earlier in 2011. Our recently assembled North American sales management team under the leadership of Michael Poole has been executing effectively, and their strategies are generating improved performance. On an annual basis, our U.S. revenue increased 21% compared to 2010. Our 19% international growth was primarily sourced from our performance in Australia, Japan and Canada. Our international revenue growth during the fourth quarter was partially offset by a decline in our revenue from Europe due to restructuring of our European sales team. With the improvements being implemented there, we anticipate our European business to be back on a growth trajectory in 2012.The second key contributor was the recent introduction of new products. Our GenesisPlus for toenail fungus targeted to podiatrists continues to perform well. In addition, the toenail fungus product is also used for warts and other rejuvenation procedures. During the quarter, we continued to see significant revenue contribution from this product sourced primarily from the U.S. business. Our premier vascular system, Excel V, that provides practitioners with the ability to treat all vascular conditions, both on the face and body, continues to gain traction in the marketplace. We remain in early-stage launch of this product and are expanding our installed base of reference sites.